OR WAIT null SECS
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 28, 2022.
Two phase 3 studies, BE OPTIMAL and BE COMPLETE, evaluated bimekizumab in adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders.
James Woody, MD, PhD, explains the benefits of treating Dupuytren’s disease with anti-tumor necrosis factor (TNF).
Clinicians give their opinions on patient-reported outcome measures regarding both initial diagnosis and management of patients with rheumatic disease.
Investigators conducted a meta-analysis to determine the association between psoriasis and an eventual psoriatic arthritis diagnosis.
COVID-19 has raised additional concerns for rheumatologists, especially regarding health care for patients with rheumatic diseases.